$TNDM

Tandem Diabetes Care (TNDM) shares rose about 19% after the company reported Q2 results with higher revenue of $254.6 million (+5.8% YoY) and improved profitability. Operating margin improved to -5.4% from -21.5%, adjusted EBITDA was $6.42 million versus $3.52 million expected, and GAAP EPS loss was -$0.31. Full-year revenue guidance was reaffirmed at a $1.08 billion midpoint.

Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 CY2026 revenue of $254.6 million, up 5.8% year over year and in line with Wall Street expectations. Full-year revenue guidance was $1.08 billion at the midpoint, near analyst estimates. GAAP EPS was a loss of $0.31, matching consensus. Adjusted operating margin was negative 5.4%.

TANDEM DIABETES CARE INC (TNDM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-q2earningsrelease2026.htm EX-99.1 Document Exhibit 99.1 Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2026 Financial Results San Diego,

Tandem Diabetes Care (NASDAQ: TNDM) is set to report earnings Thursday after market close. The prior quarter showed revenue of $247.2 million, up 5.5% year over year, and it beat analysts’ revenue and EPS estimates, with full-year guidance meeting expectations. For the upcoming quarter, analysts expect 5.4% revenue growth and an average price target of $28.53 versus $20.16.

Medical device stocks fell after HCA Healthcare reported preliminary Q2 results with weaker-than-expected surgical volumes. GE Healthcare, Intuitive Surgical, Stryker, Globus Medical and Medtronic dropped 4.7% to 7%, with other peers also down. Wells Fargo analyst Larry Biegelsen expects further declines as demand concerns are likely to be discussed on earnings calls.

Tandem Diabetes Care (NASDAQ: TNDM) said its t:slim X2 insulin pump with Control-IQ+ is now compatible with Abbott’s FreeStyle Libre 3 Plus sensor in the UK, Switzerland, Sweden, Finland, and Italy. Tandem expects more countries in 2026, including Belgium, the Netherlands, and Germany. The sensor sends readings every minute and can be worn up to 15 days.

Tandem Diabetes Care shares rose 13.8% after Wells Fargo upgraded the stock to Overweight from Equal Weight and raised its price target to $27 from $21, citing a better outlook for the pharmacy channel. The bank said Tandem rebuilt formulary coverage from 0% to ~40% in one off-cycle quarter. Early Q2 data showed April sales volume above March.

Tandem Diabetes Care (TNDM) shares rose 13.8% in the afternoon after Wells Fargo upgraded the stock to Overweight from Equal Weight and raised its price target to $27 from $21, following a management meeting. The bank cited improving pharmacy-channel outlook, including rebuilding formulary coverage to ~40% from zero in one off-cycle quarter. Early Q2 data showed April sales volume above March.

Morgan Stanley upgraded Dell to Equal Weight from Underweight and set a $448 target (from $170), citing Dell’s Q1 results and a Taiwan visit as signs it’s managing the semiconductor supply shortage better than peers. Other moves: Guggenheim raised Zscaler to Buy ($214); Citi to Buy Kohl’s ($22); Wells Fargo to Overweight Tandem Diabetes ($27); Truist to Outperform Federal Realty ($130). Truist cut Accenture to Hold ($210); Stephens cut Campbell’s to Equal Weight ($21). Texas Capital cut Caesars

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.